Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Net Revenue	$ 18,536,638	$ 15,521,917
Cost of goods sold	1,890,046	2,125,659
Gross profit	16,646,592	13,396,258
Operating expenses
Selling, general and administrative expenses	16,192,259	12,969,069
Research and development	946,298	1,317,324
Depreciation and amortization	1,105,420	778,875
Change in fair value of earnout liabilities	(65,678)	(452,687)
Total operating expenses	18,178,299	14,612,581
Operating loss	(1,531,707)	(1,216,323)
Other expense
Interest expense and other	(267,336)	(6)
Total other expense	(267,336)	(6)
Net loss	(1,799,043)	(1,216,329)
Less: Net loss attributable to noncontrolling interest	(34,859)	(38,429)
Net loss attributable to Sanara MedTech shareholders	$ (1,764,184)	$ (1,177,900)
Net loss per share of common stock, basic	$ (0.21)	$ (0.14)
Net loss per share of common stock, diluted	$ (0.21)	$ (0.14)
Weighted average number of common shares outstanding, basic	8,419,528	8,173,784
Weighted average number of common shares outstanding, diluted	8,419,528	8,173,784